Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.48 |
| ▸ | IDH2 | P48735 | 4/20 | 0.48 |
| ▸ | KCNH3 | Q9ULD8 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15102556 | 1.00 | IDH1 (0.48) | IDH1IDH2KCNH3SYKCCNT1 | |
| SCHEMBL16391828 | 0.87 | PTGS2 (0.43) | IDH1IDH2SYKCCNT1CCNE1 | |
| SCHEMBL15102544 | 0.83 | IDH1 (0.52) | IDH1IDH2KCNH3CCNT1CCNE1 | |
| SCHEMBL15102388 | 0.82 | KCNH3 (0.55) | IDH1IDH2KCNH3SYKCCNT1 | |
| SCHEMBL29560264 | 0.81 | IDH1 (0.71) | IDH1IDH2SYK | |
| SCHEMBL15102434 | 0.81 | IDH1 (0.71) | IDH1IDH2SYK | |
| SCHEMBL29560634 | 0.81 | IDH1 (0.61) | IDH1IDH2 | |
| SCHEMBL15102252 | 0.81 | IDH1 (0.61) | IDH1IDH2 | |
| SCHEMBL15102540 | 0.80 | IDH1 (0.53) | IDH1IDH2KCNH3SYKCCNT1 | |
| SCHEMBL29561157 | 0.80 | IDH1 (0.53) | IDH1IDH2KCNH3SYKCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| CN-115536635-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-30 | — | — | CN | disclosed |
| CN-115521264-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-27 | — | — | CN | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-03 | — | — | US | disclosed |
| CN-114933585-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-08-23 | — | — | CN | disclosed |
| CN-108912066-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2022-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885KCNH3 4722/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885KCNH3 4722/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885KCNH3 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.